A Markov-perfect equilibrium model of the impacts of price controls on the performance of the pharmaceutical industry

RAND Journal of Economics

Volumn 43, Issue 1, 2012, Pages 110-138

  Filson, Darren ^a  

^a CLAREMONT MCKENNA COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84859249371     PISSN: 07416261     EISSN: 17562171     Source Type: Journal    
DOI: 10.1111/j.1756-2171.2012.00159.x     Document Type: Article

References (53)

1. Abbott, T.A. and Vernon, J.A. The Cost of U.S. Pharmaceutical Price Regulation: A Financial Simulation Model of R&D Decisions. Managerial and Decision Economics, Vol. 28 (2007), pp. 293-306.
2. Acemoglu, D. and Linn, J. Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry. Quarterly Journal of Economics, Vol. 119 (2004), pp. 1049-1090.
3. Ackerberg, D.A. and Rysman, M. Unobserved Product Differentiation in Discrete-Choice Models: Estimating Price Elasticities and Welfare Effects. RAND Journal of Economics, Vol. 36 (2005), pp. 771-788.
4. Bajari, P. and Benkard, C.L. Demand Estimation with Heterogeneous Consumers and Unobserved Product Characteristics: A Hedonic Approach. Journal of Political Economy, Vol. 113 (2005), pp. 1239-1276.
5. Ben-Akiva, M. Structure of Passenger Travel Demand Models." PhD Dissertation, MIT, 1973.
6. Benkard, C.L. A Dynamic Analysis of the Market for Wide-Bodied Commercial Aircraft. Review of Economic Studies, Vol. 71 (2004), pp. 581-611.
7. Berndt, E.R., Glennerster, R., Kremer, M.R., Lee, J., Levine, R., Weizsacker, G., and Williams, H. Advanced Market Commitments for Vaccines against Neglected Diseases: Estimating Costs and Effectiveness." Health Economics, Vol. 16 (2007), pp. 491-511
8. Berry, S. and Pakes, A. The Pure Characteristics Demand Model. International Economic Review, Vol. 48 (2007), pp. 1193-1225.
9. Berry, S. and Pakes, A., Levinsohn, J., and Pakes, A. Automobile Prices in Market Equilibrium. Econometrica, Vol. 63 (1995), pp. 841-890.
10. Brouwers, C.-A., Silverstein, M.B., and Wolff, T. Adverse Consequences of OECD Government Interventions in Pharmaceutical Markets on the U.S. Economy and Consumer." White Paper, Boston Consulting Group, 2004.
11. Cameron, A.C. and Trivedi, P.K. Microeconometrics: Methods and Applications. New York : Cambridge University Press, 2005.
12. Central Intelligence Agency. (CIA). "CIA World FactBook." 2009.
13. Ching, A. A Dynamic Oligopoly Structural Model for the Prescription Drug Market after Patent Expiration." International Economic Review, Vol. 51 (2010), pp. 1175-1207
14. Cutler, D.M. and McClellan, M. Is Technological Change in Medicine Worth It? Health Affairs (2001), pp. 11-29.
15. Cutler, D.M. and McClellan, M., Long, G., Berndt, E.R., Royer, J., Fournier, A.-A., Sasser, A., and Cremieux, P. The Value of Antihypertensive Drugs: A Perspective on Medical Innovation. Health Affairs, Vol. 26 (2007), pp. 97-110.
16. Danzon, P.M. and Furukawa, M.F. Prices and Availability of Pharmaceuticals: Evidence from Nine Countries. Health Affairs, Vol. 22 (2003 July-August Supplement), pp. 521-536.
17. Danzon, P.M. and Furukawa, M.F., Wang, Y.R., and Wang, L. The Impact of Price Regulation on the Launch Delay of New Drugs-Evidence from Twenty-Five Major Markets in the 1990s. Health Economics, Vol. 14 (2005), pp. 269-292.
18. Dill, G. Medicare Prescription Drug Benefit Summary of USP Approach and Methodology to the Model Guidelines Version 4.0." Report, United States Pharmacopeial Convention, 2008.
19. DiMasi, J.A. and Grabowski, H.G. The Cost of Biopharmaceutical R&D: Is Biotech Different? Managerial and Decision Economics, Vol. 28 (2007), pp. 469-479.
20. DiMasi, J.A. and Grabowski, H.G., Hansen, R.W., and Grabowski, H.G. The Price of Innovation: New Estimates of Drug Development Costs. Journal of Health Economics, Vol. 22 (2003), pp. 151-185.
21. Domencich, T. and McFadden, D. Urban Travel Demand: A Behavioral Analysis. Amsterdam : North Holland, 1975.
22. Ericson, R. and Pakes, A. Markov-Perfect Industry Dynamics: A Framework for Empirical Work. Review of Economic Studies, Vol. 62 (1995), pp. 53-82.
23. Filson, D. and Masia, N. The Effects of Profit-Reducing Policies on Firm Survival, Financial Performance, and New Drug Introductions in the Research-Based Pharmaceutical Industry. Managerial and Decision Economics, Vol. 28 (2007), pp. 329-351.
24. Giaccotto, C., Santerre, R.E., and Vernon, J.A. Drug Prices and Research and Development Investment Behavior in the Pharmaceutical Industry. Journal of Law and Economics, Vol. 48 (2005), pp. 195-214.
25. Gilbert, J. and Rosenberg, P. Addressing the Innovation Divide: Imbalanced Innovation." Report, Bain & Company, 2004.
26. Gowrisankaran, G. and Town, R.J. Dynamic Equilibrium in the Hospital Industry. Journal of Economics & Management Strategy, Vol. 6 (1997), pp. 45-74.
27. Grabowski, H.G. and Kyle, M. Generic Competition and Market Exclusivity Periods in Pharmaceuticals. Managerial and Decision Economics, Vol. 28 (2007), pp. 491-502.
28. Grabowski, H.G. and Kyle, M. and Vernon, J.M. Pioneers, Imitators, and Generics-A Simulation Model of Schumpeterian Competition. Quarterly Journal of Economics, Vol. 102 (1987), pp. 491-525.
29. Grabowski, H.G. and Kyle, M. and Grabowski, H.G. and Kyle, M.. Brand Loyalty, Entry and Price Competition in Pharmaceuticals after the 1984 Drug Act. Journal of Law and Economics, Vol. 35 (1992), pp. 331-350.
30. Grabowski, H.G. and Kyle, M. and Grabowski, H.G. and Kyle, M.. Longer Patents for Increased Generic Competition in the U.S. PharmacoEconomics, Vol. 10, Suppl. (1996), pp. 110-123.
31. Grabowski, H.G. and Kyle, M., Grabowski, H.G. and Kyle, M., and DiMasi, J.A. Returns on Research and Development for 1990s New Drug Introductions. PharmacoEconomics, Vol. 20, Suppl. 3 (2002), pp. 11-29.
32. Hopenhayn, H.A. Entry, Exit, and Firm Dynamics in Long-Run Equilibrium. Econometrica, Vol. 60 (1992), pp. 1127-1150.
33. Hughes, J.W., Moore, M.J., and Snyder, E.A. 'Napsterizing' Pharmaceuticals: Access, Innovation, and Consumer Welfare." Working Paper no. 9229, National Bureau of Economic Research, 2002.
34. Kremer, M. Patent Buyouts: A Mechanism for Encouraging Innovation. Quarterly Journal of Economics, Vol. 113 (1998), pp. 1137-1167.
35. Lakdawalla, D. and Sood, N. Innovation and the Welfare Effects of Public Drug Insurance. Journal of Public Economics, Vol. 93 (2009), pp. 541-548.
36. Lakdawalla, D. and Sood, N., Goldman, D.P., Michaud, P.-C., Sood, N., Lempert, R., Cong, Z., De Vries, H., and Gutierrez, I. U.S. Pharmaceutical Policy in a Global Marketplace. Health Affairs, Vol. 28 (2009), pp. W138-W150.
37. Lichtenberg, F.R. Pharmaceutical Innovation, Mortality Reduction, and Economic Growth." In R.H. Topel and K.M. Murphy, eds., Measuring the Gains from Medical Research: An Economic Approach. Chicago : University of Chicago Press, 2003.
38. Lucas, R.E., Jr. Econometric Policy Evaluation: A Critique. Carnegie Rochester Conference Series on Public Policy, Vol. 1 (1976), pp. 19-46.
39. McFadden, D. Conditional Logit Analysis of Qualitative Choice Behavior." In P. Zarembka, ed., Frontiers in Econometrics. New York : Academic Press, 1973.
40. McFadden, D.. Computing Willingness-to-Pay in Random Utility Models." In J.R. Melvin, J.C. Moore, and R. Riezman, eds., Trade, Theory, and Econometrics: Essays in Honor of John S. Chipman. New York : Routledge, 1999.
41. Murphy, K.M. and Topel, R.H. The Economic Value of Medical Knowledge." In R.H. Topel and K.M. Murphy, eds., Measuring the Gains from Medical Research: An Economic Approach. Chicago : University of Chicago Press, 2003.
42. Murphy, K.M. and Topel, R.H. and Murphy, K.M. and Topel, R.H.. The Value of Health and Longevity. Journal of Political Economy, Vol. 114 (2006), pp. 871-904.
43. Nevo, A. New Products, Quality Changes, and Welfare Measures Computed from Estimated Demand Systems. Review of Economics & Statistics, Vol. 85 (2003), pp. 266-275.
44. Pakes, A. and McGuire, P. Computing Markov-Perfect Equilibria: Numerical Implications of a Dynamic Differentiated Products Model. RAND Journal of Economics, Vol. 25 (1994), pp. 555-589.
45. PAREXEL. PAREXEL's Bio/Pharmaceutical R&D Statistical Sourcebook 2010/2011. Waltham, Mass. : PAREXEL, 2010.
46. Petrin, A. Quantifying the Benefits of New Products: The Case of the Minivan. Journal of Political Economy, Vol. 110 (2002), pp. 705-729.
47. Scotchmer, S. Innovation and Incentives. Cambridge, Mass. : MIT Press, 2004.
48. Small, K.A. and Rosen, H.S. Applied Welfare Economics with Discrete Choice Models. Econometrica, Vol. 49 (1981), pp. 105-130.
49. Sood, N., De Vries, H., Gutierrez, I., Lakdawalla, D.N., and Goldman, D.P. The Effect of Regulation on Pharmaceutical Revenues: Experience in Nineteen Countries. Health Affairs, Vol. 28 (2009), pp. W125-W137.
50. Stokey, N.L. and Lucas, R.E., Jr., with Prescott, E.C. Recursive Methods in Economic Dynamics. Cambridge, Mass. : Harvard University Press, 1989.
51. Tan, W. The Effects of Taxes and Advertising Restrictions on the Market Structure of the U.S. Cigarette Market. Review of Industrial Organization, Vol. 28 (2006), pp. 231-251.
52. U.S. Department of Commerce, International Trade Administration. "Pharmaceutical Price Controls in OECD Countries: Implications for U.S. Consumers, Pricing, Research and Development, and Innovation." 2004.
53. Vernon, J.A. Examining the Link between Price Regulation and Pharmaceutical R&D Investment. Health Economics, Vol. 14 (2005), pp. 1-16.